V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160016489 | 160020150 | 1.54 | 87 | null | 2017-08-06 | 2017-10-16 | null | null | null | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 100100749 |
| 160016503 | 160020151 | 1.56 | 78.7 | null | 2018-04-04 | 2018-04-04 | Etoposide oral | 02 | null | TRAMETINIB | 101759217 |
| 160016540 | 160020152 | 0 | 39 | Palliative (P) | 2021-12-13 | 2022-01-18 | STS Rhabdomyosarcoma RMS 2005 VA | N | N | DACTINOMYCIN + VINCRISTINE | 101003034 |
| 160016547 | 160020153 | 1.64 | 70.6 | Palliative (P) | 2019-11-27 | 2019-12-21 | Trial Unspecified | 02 | N | DACTINOMYCIN + DOXORUBICIN + IFOSFAMIDE + VINCRISTINE | 100387025 |
| 160016584 | 160020154 | 1.58 | 71.8 | Palliative (P) | 2020-09-30 | 2020-10-01 | STS Non-Rhabdo EpSSG 2005 Ifos | 02 | N | VINCRISTINE | 100622382 |
| 160016587 | 160020155 | 1.79 | 72 | null | 2021-12-20 | 2022-03-25 | STS Rhabdomyosarcoma RMS 2005 IVADo | 02 | null | MELPHALAN + TREOSULPHAN | 101439690 |
| 160016601 | 160020156 | 1.67 | 68.5 | Curative (C) | 2017-10-05 | 2017-10-06 | CAPECITABINE + TEMOZOLOMIDE | 02 | N | RMS 2005 TRIAL | 101288706 |
| 160016613 | 160020157 | 1.64 | 74.9 | Curative (C) | 2017-07-22 | 2017-08-01 | null | null | null | RITUXIMAB | 101487963 |
| 160016634 | 160020158 | 1.59 | 51 | null | 2018-09-17 | 2018-10-08 | Capecitabine | 02 | null | NIRAPARIB | 101340491 |
| 160016636 | 160020159 | 0 | 80 | Curative (C) | 2021-04-13 | 2021-05-23 | null | 02 | null | PEMBROLIZUMAB | 100921383 |
| 160016641 | 160020161 | 1.67 | 42.2 | Adjuvant (A) | 2018-03-22 | 2018-04-21 | Cisplatin + Paclitaxel | null | Y | GEMCITABINE | 100119618 |
| 160016655 | 160020162 | null | null | null | 2019-09-15 | 2019-10-06 | Niraparib | null | null | NB HRNBL-1 ISOTRETINOIN | 100203446 |
| 160016710 | 160020163 | 0 | 8.8 | Palliative (P) | 2017-02-06 | 2017-03-27 | Trial Unspecified | 02 | N | METHOTREXATE | 100954690 |
| 160016728 | 160020164 | 1.89 | 72.2 | Palliative (P) | 2020-02-14 | 2020-03-01 | STS Non-Rhabdo EpSSG 2005 Vcy | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101189672 |
| 160016745 | 160020165 | 1.63 | 70 | Palliative (P) | 2022-02-22 | 2022-02-28 | ETOP 13-18 BEAT-meso Trial | 02 | N | CABOZANTINIB | 101560703 |
| 160016749 | 160020166 | null | 81.1 | null | 2019-02-25 | 2019-09-08 | CARBOPLATIN + VINORELBINE | 02 | null | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100080250 |
| 160016779 | 160020167 | 0.88 | 69.8 | Curative (C) | 2021-11-13 | 2021-11-13 | EW Rel rEECur Topotecan/Cyclophosphamide | 02 | N | CYCLOPHOSPHAMIDE + TOPOTECAN | 100909788 |
| 160016784 | 160020168 | 1.66 | 101.6 | 03 | null | null | STS Rhabdomyosarcoma RMS 2005 IVADo | 02 | N | STS NON-RHABDO EPSSG 2005 IVA | 101548082 |
| 160016811 | 160020169 | 0 | 57.6 | Curative (C) | null | null | GEMCITABINE | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100428216 |
| 160016844 | 160020170 | 1.59 | 106 | Curative (C) | 2017-01-22 | 2017-04-13 | NB HRNBL-1 Isotretinoin | N | null | EW EUROEWING 2012 ARM B VC | 100517306 |
| 160016868 | 160020171 | 1.83 | 80.9 | 03 | 2020-10-28 | 2020-11-18 | ETOPOSIDE + RITUXIMAB | 02 | N | GEMCITABINE | 101197738 |
| 160016885 | 160020172 | 0 | 89 | null | 2020-11-17 | 2020-12-09 | Cyclophosphamide PO +Vinorelbine IV | N | null | PEMBROLIZUMAB | 101028116 |
| 160016921 | 160020173 | 1.61 | 90.2 | null | 2022-02-20 | 2022-02-27 | Cisplatin + Etoposide po | null | null | NOT MATCHED | 100601969 |
| 160016953 | 160020174 | 1.62 | 34.4 | Not known (9) | 2015-11-04 | 2016-04-21 | STS Rhabdo RMS 2005 2nd Topo Cyclo | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100054016 |
| 160016955 | 160020175 | null | 69 | Curative (C) | 2019-05-25 | 2019-05-26 | null | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVAVV | 101863220 |
| 160016959 | 160020176 | 1.82 | 89 | null | 2022-01-21 | 2022-01-28 | BEVACIZUMAB + CARBO + PACLITAXEL | 01 | null | CYCLOPHOSPHAMIDE + VINORELBINE | 100659204 |
| 160016971 | 160020177 | 1.68 | 19.4 | Palliative (P) | 2019-07-24 | 2019-12-28 | CONFIRM TRIAL | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100977599 |
| 160016975 | 160020178 | 0 | 30 | Curative (C) | 2019-12-28 | 2019-12-28 | Doxorubicin + Ifosfamide | 02 | N | DACTINOMYCIN + IFOSFAMIDE + VINCRISTINE | 100761456 |
| 160016986 | 160020179 | null | null | null | 2019-02-03 | 2019-03-06 | null | 02 | null | OLARATUMAB | 100200365 |
| 160016990 | 160020180 | null | 10.5 | null | 2022-01-30 | 2022-02-14 | Azacitidine | 2 | null | CONFIRM TRIAL | 101822042 |
| 160016996 | 160020182 | 1.61 | 79 | Curative (C) | 2021-08-21 | 2021-12-30 | GEMCITABINE | 02 | N | NIRAPARIB | 100086284 |
| 160017014 | 160020183 | 1.75 | 93.2 | null | 2016-06-29 | 2016-07-24 | Cyclophosphamide oral | 02 | null | OLARATUMAB | 101467040 |
| 160017030 | 160020184 | 0 | 82.4 | Curative (C) | 2017-10-01 | 2017-12-23 | DACARBAZINE + GEMCITABINE | 02 | null | OLARATUMAB | 101823003 |
| 160017052 | 160020185 | 1.49 | 49.3 | null | 2018-02-13 | 2019-10-06 | Eribulin | 02 | null | OLARATUMAB | 100940818 |
| 160017054 | 160020186 | 1.71 | 96.3 | null | 2022-03-07 | 2022-03-07 | Trial Unspecified | 02 | null | ERIBULIN | 101068411 |
| 160017106 | 160020187 | 1.69 | 10.2 | Palliative (P) | null | 2021-10-13 | IVA | 02 | null | TRIAL | 100451101 |
| 160017127 | 160020188 | 0 | 70.3 | Curative (C) | 2022-04-01 | 2022-04-07 | CYCLOPHOSPHAMIDE + DACTINOMYCIN + VINCRISTINE | 02 | N | EW EUROEWING 2012 ARM B VC | 101584547 |
| 160017128 | 160020189 | 1.73 | 87 | null | 2017-04-21 | 2017-04-22 | Gemcitabine 1000mg/m2 D1 8 15 | 02 | null | DACARBAZINE + GEMCITABINE | 100315424 |
| 160017140 | 160020190 | 1.62 | 54 | Palliative (P) | 2020-12-14 | 2020-12-21 | EW EuroEwing 2012 Arm B IE | 01 | N | OLAPARIB | 100022048 |
| 160017143 | 160020191 | 0 | 97.8 | null | 2022-02-05 | 2022-02-05 | EW EuroEwing 2012 Arm B IE | 01 | null | STS RHABDO RMS 2005 VIN CYCLO | 101237274 |
| 160017159 | 160020192 | 1.7 | 67.4 | Adjuvant (A) | 2021-01-12 | 2021-02-07 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | DARATUMUMAB | 101794810 |
| 160017164 | 160020193 | 0 | 65 | null | 2020-10-11 | 2020-10-17 | Trial Unspecified | 02 | null | IVADO | 100139910 |
| 160017176 | 160020194 | 1.66 | 70.8 | null | 2020-06-25 | 2020-10-02 | Irinotecan + Temozolomide | 02 | null | IVA | 100445707 |
| 160017216 | 160020196 | 0 | 81.8 | Curative (C) | 2019-09-12 | 2019-09-13 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | N | RMS 2005 TRIAL | 101196585 |
| 160017220 | 160020197 | 1.6 | 85.7 | null | 2017-01-30 | 2017-06-12 | EW Rel rEECur Gemcitabine/Docetaxel + GCSF | 02 | null | DACTINOMYCIN + DOXORUBICIN + IFOSFAMIDE + VINCRISTINE | 101402976 |
| 160017277 | 160020198 | 1.68 | 72.5 | Curative (C) | 2021-10-24 | 2022-04-01 | PEMBROLIZUMAB | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVA | 100030899 |
| 160017287 | 160020199 | 1.64 | 19.1 | Palliative (P) | 2018-10-01 | 2018-10-02 | NEMO TRIAL | 02 | N | STS RHABDOMYOSARCOMA RMS 2005 IVADO | 101651506 |
| 160017328 | 160020200 | 1.59 | 77.3 | Palliative (P) | 2021-05-17 | 2021-07-06 | IVADo | 02 | null | STS RHABDOMYOSARCOMA RMS 2005 IVA | 101659424 |
| 160017375 | 160020201 | 1.7 | 25 | Palliative (P) | 2019-11-18 | 2020-04-05 | NB HRNBL-1 ch14.18/CHO only (trial) | 02 | N | LANREOTIDE | 101613656 |
| 160017378 | 160020202 | 1.3 | null | Palliative (P) | 2018-07-28 | 2019-01-26 | ETOPOSIDE | 02 | N | OLAPARIB | 100810764 |